23 January 2018 - - Bridgewater, New Jersey-based generic pharmaceutical manufacturer Amneal Pharmaceuticals has launched budesonide capsules, 3 mg, an AB-rated equivalent to Entocort EC, the company said.
Budesonide is the first product launch of the new year for Amneal Pharmaceuticals.
Budesonide capsules are now shipping to wholesalers, distributors and direct to the trade.
In 2017, the company received 45 ANDA approvals (39 final and 6 tentative) and launched 35 product families--nine of these by its injectables subsidiary Amneal Biosciences.
Privately-held Amneal Pharmaceuticals is a US generics pharmaceutical manufacturer with more than 5,000 employees in North America, Asia and Europe, working together to bring high-quality affordable medicines to patients worldwide.
Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas.